新辅助立体定向放疗对比常规放化疗对交界可切除或局部晚期胰腺癌术后并发症的影响
该回顾性研究纳入2008至2015年在约翰霍普金斯医院接受新辅助化疗联合立体定向体部放疗或常规放化疗后行胰腺切除术的168例交界可切除或局部晚期胰腺导管腺癌患者。
要点
- 新辅助立体定向放疗与常规放化疗后严重并发症发生率相当。
- 立体定向放疗组更多为局部晚期且需血管切除,但并发症未增加。
- 两组术后出血或感染无显著差异。
核心结论
- 对于交界可切除或局部晚期胰腺导管腺癌,新辅助立体定向体部放疗对比常规放化疗,围术期并发症发生率相当。
研究设计与样本
- 回顾性研究纳入2008至2015年约翰霍普金斯医院接受新辅助化疗联合放疗后行胰腺切除术的168例交界可切除或局部晚期胰腺导管腺癌患者。
主要发现
- 两组术后出血或感染无显著差异。
临床怎么用
- 对于交界可切除或局部晚期胰腺癌,新辅助立体定向体部放疗可作为常规放化疗的替代选择,不增加严重并发症风险。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 单中心研究,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy. METHODS: Patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy with stereotactic body radiation therapy or chemoradiation therapy followed by pancreatectomy at the Johns Hopkins Hospital between 2008 and 2015 were included. Predictive factors for severe complications (Clavien grade ≥ III) were assessed by univariate and multivariate analyses. RESULTS: A total of 168 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma underwent neoadjuvant chemotherapy and RT followed by pancreatectomy. Sixty-one (36%) patients underwent stereotactic body radiation therapy and 107 (64%) patients received chemoradiation therapy. Compared with the chemoradiation therapy cohort, the neoadjuvant stereotactic body radiation therapy cohort was more likely to have locally advanced pancreatic ductal adenocarcinoma (62% vs 43% P = .017) and require a vascular resection (54% vs 37%, P = .027). Multiagent chemotherapy was used more commonly in the stereotactic body radiation therapy cohort (97% vs 75%, P < .001). Postoperative complications (Clavien grade ≥ III 23% vs 28%, P = .471) were similar between stereotactic body radiation therapy and chemoradiation therapy cohort. No significant difference in postoperative bleeding or infection was noted in either group. CONCLUSION: Compared with chemoradiation therapy, neoadjuvant stereotactic body radiation therapy appears to offer equivalent rates of perioperative complications in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma despite a greater percentage of locally advanced disease and more complex operative treatment.
引用
- Blair AB, Rosati LM, Rezaee N, et al. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery. 2018. PMID: 29395234. doi:10.1016/j.surg.2017.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。